Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIMOCOVID-1 trial of rimonabant for cognitive impairment in post-COVID-19 syndrome
2023-507870-42-00Phase 2Authorised
- Sponsor
- Sinfatin
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID syndrome comparing Rimonabant with Placebo comparator (2 arms). Primary endpoint: Change from baseline in Symbol Digit Modalities Test total score. Planned start Oct 2026; status: authorised.
02
Drugs
rimonabant
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2023-507870-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507870-42-00.